69.45
+1.24%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Laboratorios Farmaceuticos ROVI
Its shares trade on BME under the ticker ROVI.MC. It has been listed since 26 October 2007. In the fiscal year to 31 December 2025, it reported revenue of €743.5m and net income of €140.4m. At that date it held total assets of €955.7m and shareholders' equity of €664.4m.
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Oct 2007
- Employees
- 1,419
- Website
- rovi.es ↗
Leadership
Pay as last reported
- Mr. Juan Lopez-Belmonte EncinaExecutive Chairman of the Board, Chief Executive Officer, since 2007€1.9m
- Mr. Javier Lopez-Belmonte EncinaFirst Executive Vice Chairman of the Board, Chief Financial Officer, General Manager of Industrial Operations, since 2001€729,000
- Mr. Ivan Jorge Lopez-Belmonte EncinaSecond Executive Vice Chairman of the Board, Chief Commercial and Development Officer, since 2007€721,000
- Ms. Marta CamposDirector - Finance and Investor Relations
- Ms. Mercedes Benitez Del Castillo SanchezDirector - Legal
- Ms. Maria Rosario Perucha PerezDirector - Marketing
- Mr. Francisco Javier Angulo GarciaDirector - Human Resources
- Mr. Pedro Carretero TrilloDirector - Hospital Network
- Mr. Miguel Angel Castillo San RomanDirector - International and Business Development
- Ms. Marta Garcia MolynuexDirector - Records
- Mr. Ibon Gutierro AdurizDirector - Preclinical Research
- Ms. Aranzazu Lozano PirrongelliDirector - Internal Audit, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 97
- Social
- 99
- Governance
- 47
- Direct emissions (scope 1)
- 9,565.8 t
- Energy emissions (scope 2)
- 9,243.18 t
- Value chain emissions (scope 3)
- 12,099.63 t
- Women in the workforce
- 52.52617%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Laboratorios Farmaceuticos ROVI SA has several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Laboratorios Farmaceuticos ROVI SA also has some weaknesses:
Opportunities
- There are several opportunities available for Laboratorios Farmaceuticos ROVI SA:
Threats
- Laboratorios Farmaceuticos ROVI SA faces certain threats that may impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.